Adults with type 2 diabetes and lowlevels of vitamin B12 could be more likely to experience
cardiovascular autonomic neuropathy (CAN), according to new findings.
CAN occurs when nerve damage affects the heart, which can be caused
by prolonged hyperglycemia over several years in people with
diabetes.
The Steno Diabetes Centre in Denmark sought to investigate the association of vitamin B12 deficiency and CAN in type 2 diabetes patients, so they analyzed data from 469 patents, all of whom were screened for CAN between June 2013 and December 2014.
The Steno Diabetes Centre in Denmark sought to investigate the association of vitamin B12 deficiency and CAN in type 2 diabetes patients, so they analyzed data from 469 patents, all of whom were screened for CAN between June 2013 and December 2014.
Study participants also provided blood
samples for serum vitamin B12 measurements, with researchers
analyzing associations between deficiency and measures of neuropathy.
Those participants who were treated
with metformin and/or proton pump inhibitors (PPIs) were more likely
to have significantly lower levels of vitamin B12 compared to
participants who were not on treatment. Additionally, vitamin B12
levels were linked to a lower diagnosis rate of CAN in models
adjusted for sex, age, alcohol consumption, and diabetes duration.
The scientists also noted that a 25
pmol/L higher level of vitamin B12 was associated with a 21 per cent
increase in the cardiovascular autonomic reflex test for deep
breathing and a decrease in five-minute resting heart rate.
These findings remained after excluding
patients that had received B12 supplements and following adjustment
for confounding factors such as HbA1c, total cholesterol, smoking
status, and triglyceride levels.
"The present study presents
evidence that patients with type 2 diabetes who are treated with
metformin and proton pump inhibitors have lower serum levels of
vitamin B12 than patients not treated with these drugs,"
said the researchers.
"These findings support a growing amount of evidence that these drug therapies are a cause of vitamin B12 deficiency."
"These findings support a growing amount of evidence that these drug therapies are a cause of vitamin B12 deficiency."
Studies are currently underway to
assess whether a lack of vitamin B12 has causal role in the
development of patients with CAN.
The results were published in the Journal of Diabetes and its Complications.
The results were published in the Journal of Diabetes and its Complications.
No comments:
Post a Comment